• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.

作者信息

Zhang Lele, Gao Zhen, Pan Hong, Li Ruonan, Fang Liwei, Li Weiwang, Zhao Jingyu, Yu Xiao, Kuang Zhexiang, Nie Neng, Li Jianping, Huang Jinbo, Zhao Xin, Ge Meili, Zheng Yizhou, Luo Yuechen, Shi Jun

机构信息

State Key Laboratory of Experimental Hematology, Tianjin, China.

Blood Diseases Hospital, Tianjin, China.

出版信息

N Engl J Med. 2025 Jun 12;392(22):2282-2284. doi: 10.1056/NEJMc2502297.

DOI:10.1056/NEJMc2502297
PMID:40499177
Abstract
摘要

相似文献

1
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.用于CD19嵌合抗原受体T细胞疗法后自身免疫性溶血性贫血的靶向B细胞成熟抗原的T细胞衔接器
N Engl J Med. 2025 Jun 12;392(22):2282-2284. doi: 10.1056/NEJMc2502297.
2
[Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].[抗BCMA单次输注与抗CD19嵌合抗原受体T细胞联合输注用于复发/难治性多发性骨髓瘤免疫重建的比较]
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):733-738. doi: 10.3760/cma.j.issn.0253-2727.2021.09.004.
3
Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy.溶瘤单纯疱疹病毒递送CD19和BCMA的双嵌合抗原受体（CAR）靶点以及免疫调节剂，以增强实体瘤联合CAR T细胞疗法的治疗效果。
Front Oncol. 2022 Oct 24;12:1037934. doi: 10.3389/fonc.2022.1037934. eCollection 2022.
4
Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.抗BCMA和抗CD19嵌合抗原受体T细胞联合疗法治疗复发/难治性多发性骨髓瘤的临床疗效与安全性：一项系统评价和荟萃分析
Front Oncol. 2024 Apr 8;14:1355643. doi: 10.3389/fonc.2024.1355643. eCollection 2024.
5
Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma.新型双串联CD19/BCMA嵌合抗原受体T细胞的特性研究，有望用于治疗多发性骨髓瘤。
Biomark Res. 2020 May 13;8:14. doi: 10.1186/s40364-020-00192-6. eCollection 2020.
6
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.联合输注靶向CD19和靶向BCMA的嵌合抗原受体T细胞治疗难治性系统性红斑狼疮：一项1期试验
Nat Med. 2025 Nov;31(11):3725-3736. doi: 10.1038/s41591-025-03937-8. Epub 2025 Sep 24.
7
Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial.抗BCMA/CD19嵌合抗原受体T细胞疗法治疗难治性全身型重症肌无力：一项单臂1期试验
EClinicalMedicine. 2025 Oct 31;90:103621. doi: 10.1016/j.eclinm.2025.103621. eCollection 2025 Dec.
8
BCMA-CAR Therapy for Multiple Myeloma in NOG Mice Prevents the Progression of Anemia and Bone Lesions.用于NOG小鼠多发性骨髓瘤的BCMA嵌合抗原受体疗法可预防贫血和骨病变的进展。
Hum Gene Ther. 2025 Jun;36(11-12):902-913. doi: 10.1089/hum.2024.263. Epub 2025 May 15.
9
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.一名复发性特发性炎症性肌病患者在接受初始和重复的CD19嵌合抗原受体T细胞（CAR T）治疗后使用BCMA CAR T细胞治疗的情况。
Nat Med. 2025 Apr 17. doi: 10.1038/s41591-025-03718-3.
10
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.ARI0003：用于治疗非霍奇金淋巴瘤的共转导CD19/BCMA双靶点嵌合抗原受体T细胞。
Mol Ther. 2025 Jan 8;33(1):317-335. doi: 10.1016/j.ymthe.2024.11.028. Epub 2024 Nov 19.

引用本文的文献

1
Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug.
HLA. 2026 Jan;107(1):e70550. doi: 10.1111/tan.70550.
2
Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies.早期鞘内注射地塞米松和甲氨蝶呤作为CAR-T细胞治疗后免疫效应细胞相关神经毒性综合征的有效治疗方法。
Front Immunol. 2025 Dec 17;16:1716317. doi: 10.3389/fimmu.2025.1716317. eCollection 2025.
3
Chimeric antigen receptor (CAR) therapies for precise eradication of pathogenic cells in autoimmunity.用于精确清除自身免疫性疾病中致病细胞的嵌合抗原受体（CAR）疗法。
Arthritis Res Ther. 2025 Dec 6;28(1):8. doi: 10.1186/s13075-025-03711-8.
4
CAR T Cell Therapy for Rheumatoid Arthritis.用于类风湿关节炎的嵌合抗原受体T细胞疗法
Clin Rev Allergy Immunol. 2025 Nov 19;68(1):100. doi: 10.1007/s12016-025-09113-7.
5
Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial.抗BCMA/CD19嵌合抗原受体T细胞疗法治疗难治性全身型重症肌无力：一项单臂1期试验
EClinicalMedicine. 2025 Oct 31;90:103621. doi: 10.1016/j.eclinm.2025.103621. eCollection 2025 Dec.